@article{612205f0976a4a43b9db1c54004dc35e,
title = "Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).",
author = "Cortes, \{Jorge E.\} and Stefan Faderl and John Pagel and Jung, \{Chul Won\} and Sung-Soo Yoon and Youngil Koh and Pardanani, \{Animesh Dev\} and Hauptschein, \{Robert S\} and Kyoung-June Lee and Je-Hwan Lee",
note = "Background: CWP232291, a novel peptidomimetic small molecule identified via a phenotypic drug discovery screen, shows selective inhibitory activity at submicromolar levels on a Wnt gene reporter and decreases expression of the β-catenin target genes, cyclin D1 and survivin. It has broad anti-cancer efficacy in vitro, with significant preclinical tumor regression outperforming standard cytotoxic AML drugs.",
year = "2015",
month = may,
day = "20",
language = "American English",
volume = "33",
journal = "Journal of Clinical Oncology",
}